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BACKGROUND: Increasing evidence implicates overactivation of RhoA as a critical
component of the pathogenesis of hypertension. Although a substantial body of work
has established that Rac1 functions antagonize RhoA in a broad range of
physiological processes, the role of Rac1 in the regulation of vascular tone and blood
pressure is not fully elucidated. METHODS AND RESULTS: To define the role of
Rac1 in vivo in vascular smooth muscle cells (vSMC), we generated smooth muscle
(SM)-specific Rac1 knockout mice (SM-Rac1-KO) and performed radiotelemetric
blood pressure recordings, contraction measurements in arterial rings, vSMC
cultures and biochemical analyses. SM-Rac1-KO mice develop high systolic blood
pressure sensitive to Rho kinase inhibition by fasudil. Arteries from SM-Rac1-KO
mice are characterized by a defective NO-dependent vasodilation and an
overactivation of RhoA/Rho kinase signaling. We provide evidence that Rac1
deletion-induced hypertension is due to an alteration of cGMP signaling resulting
from the loss of Rac1-mediated control of type 5 PDE activity. Consequently, cGMP-
dependent phosphorylation and binding of RhoA with its inhibitory partner, the
phosphatase-RhoA interacting protein (p116(RIP3)), are decreased. CONCLUSIONS:
Our data reveal that the depletion of Rac1 in SMC decreases cGMP-dependent
p116(RIP3)/RhoA interaction and the subsequent inhibition of RhoA signaling. Thus,
we unveil an in vivo role of Rac1 in arterial blood pressure regulation and a new
pathway involving p116(RIP3) that contributes to the antagonistic relationship
between Rac1 and RhoA in vascular smooth muscle cells and their opposite roles in
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